Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 15, 2021Journal of Liver TransplantationOpen Access

Transarterial chemoembolization in patients with unresectable HCC was associated with decreased left ventricular ejection fraction across all tumor response groups (P<=0.01).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

The study was conducted to assess the effect of transarterial chemoembolization on cardiopulmonary functions in patients with unresectable hepatocellular carcinoma.

Does transarterial chemoembolization (TACE) affect cardiopulmonary functions in patients with unresectable hepatocellular carcinoma?

Population

300 patients with unresectable HCC candidate for treatment by TACE

Design

Prospective cohort study

Follow-up

one month

Key result

Transarterial chemoembolization in patients with unresectable HCC was associated with decreased left ventricular ejection fraction across all tumor response groups (P<=0.01).

Authors

KFKhaled FaridHEHatem ElalfyMEMahmoud El‐Bendary

Discussion

Loading...

Member takes

Overview

May warrant post-TACE echocardiographic surveillance in unresectable HCC; leaves open causal impact pending prospective trials.

Key Points

  • This study aims to evaluate the impact of transarterial chemoembolization on cardiopulmonary functions in patients with unresectable hepatocellular carcinoma.
  • 300 patients with unresectable HCC were included and treated with TACE.
  • Pulmonary function tests and echocardiography were performed pre- and post-TACE (one month after treatment).
  • Assessment of treatment response was conducted using modified Response Evaluation Criteria.
  • Significant lung restriction was noted in patients with partial response (P = 0.002) and stable disease (P = 0.014) after TACE.
  • Left ventricular strain observed in complete response patients included a decrease in left ventricular ejection fraction (P = 0.01) and global longitudinal strain (P = 0.001).
  • Patients with partial response and stable disease also demonstrated decreases in left ventricular ejection fraction (P < 0.0001 for both).

Study Design

Type

Cohort (n=300)

Structured PICO

Does transarterial chemoembolization (TACE) affect cardiopulmonary functions in patients with unresectable hepatocellular carcinoma?

P
Population
300 patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization, evaluated for cardiopulmonary function one day before and one month after treatment.
E
Exposure
Transarterial chemoembolization (TACE)
C
Comparator
Baseline (one day before TACE)
O
Outcome
Cardiopulmonary functions assessed by pulmonary function tests (PFT) and echocardiography (including LVEF and GLS) one month after TACEsurrogate

TACE for unresectable HCC is associated with early deleterious cardiopulmonary effects, including reduced LVEF and increased lung restriction, suggesting a need for cardiopulmonary monitoring.

Cite This Study

Farid et al. (2021) conducted a cohort in Unresectable hepatocellular carcinoma (n=300). Transarterial chemoembolization (TACE) vs. Baseline (one day before TACE) was evaluated on Cardiopulmonary functions (pulmonary function tests and echocardiography). Transarterial chemoembolization in patients with unresectable HCC was associated with decreased left ventricular ejection fraction across all tumor response groups (P<=0.01).

synapsesocial.com/papers/6a63f3361d33332decb372e1https://doi.org/10.1016/j.liver.2021.100063
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Radiological Response and Characteristics of Patients Diagnosed With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: An Observational Study.2025
  2. 2Efficacy and Safety of Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma (HCC) and Assessment of Health Related Quality of Life (HRQoL) using CLDQ©2024
  3. 3Clinical outcomes of transarterial chemoembolization in Child–Turcotte Pugh class A patients with a single small (≤3 cm) hepatocellular carcinoma2024 · 1 citations
  4. 4Recurrent hepatocellular carcinoma after partial hepatectomy: value of treatment with transcatheter arterial chemoembolization.1991 · 39 citations
  5. 5Retrospective Long-Term Evaluation of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma over 20 Years2024 · 2 citations